Lung Adenocarcinoma Overview

Save information for later
Sign Up

Learn About Lung Adenocarcinoma

View Main Condition: Non-Small Cell Lung Cancer (NSCLC)

What is the definition of Lung Adenocarcinoma?
Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing.
What are the alternative names for Lung Adenocarcinoma?
  • Lung adenocarcinoma
Who are the top Lung Adenocarcinoma Local Doctors?
Elite in Lung Adenocarcinoma
Dr. Ravi Salgia
Oncology
Elite in Lung Adenocarcinoma
Dr. Ravi Salgia
Oncology

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
626-256-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravi Salgia is an Oncologist in Duarte, California. Dr. Salgia is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Gastrostomy.

Elite in Lung Adenocarcinoma
Dr. Christopher G. Azzoli
Oncology | Hematology
Elite in Lung Adenocarcinoma
Dr. Christopher G. Azzoli
Oncology | Hematology

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
401-444-5435
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Azzoli is an Oncologist and a Hematologist in Providence, Rhode Island. Dr. Azzoli is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

 
 
 
 
Learn about our expert tiers
Learn More
Suresh S. Ramalingam
Elite in Lung Adenocarcinoma
Dr. Suresh S. Ramalingam
Oncology
Elite in Lung Adenocarcinoma
Dr. Suresh S. Ramalingam
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
404-778-1900
Experience:
34+ years
Languages Spoken:
English, Tamil
See accepted insurances
Offers Telehealth

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam has been practicing medicine for over 34 years and is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

View All Doctors
What are the latest Lung Adenocarcinoma Clinical Trials?
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Who is this study for: Patients with stage III non-squamous non-small cell lung cancer
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cisplatin, Durvalumab, Methoxyamine, Pemetrexed
Study Phase: Phase 2

Summary: This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agen...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Who is this study for: Patients with Melanoma
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Procedure, Biological, Other
Study Drugs: Cyclophosphamide, Fludarabine Phosphate, IL13Ralpha2-Specific Hinge-Optimized 4-1BB-co-Stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Recombinant Interleukin-2
Study Phase: Phase 1

Summary: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center